Draft Guidance on Esomeprazole Magnesium

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Esomeprazole magnesium

Dosage Form; Route: Delayed release tablet; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in vivo
   Strength: EQ 20 mg Base
   Subjects: Males and non-pregnant, non-lactating females, general population.
   Additional Comments: Applicants may consider using a reference-scaled average bioequivalence approach for Esomeprazole Magnesium Delayed Release Tablet. For the method of statistical analysis using the reference-scaled average bioequivalence approach, refer to the Progesterone Capsule Guidance.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in vivo
   Strength: EQ 20 mg Base
   Subjects: Males and non-pregnant, non-lactating females, general population.
   Additional Comments: See comments above

Analyte to measure (in appropriate biological fluid): Esomeprazole in plasma

Bioequivalence based on (90% CI): Esomeprazole

Waiver request of in-vivo testing: Not applicable

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website, available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).